DMN:FRA
Diamyd Medical AB
€0.064
arrow_upward
+1.92%(+0.0012) 1 天
11月20日, GMT+1 08:04:51 · EUR
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 DMN 生成关键数据洞见…
开盘价
€0.06
最高价
€0.06
最低价
€0.06
市值
1.36亿
平均成交量
0.00
成交量
0.00
52 周最高价
€1.80
52 周最低价
€0.05
员工人数
42
开盘价
€0.06
最高价
€0.06
最低价
€0.06
市值
1.36亿
平均成交量
0.00
成交量
0.00
52 周最高价
€1.80
52 周最低价
€0.05
员工人数
42
新闻报道
来自网络来源和新闻合作伙伴
marketscreener.com
·
47分钟前
Societe Generale sees S&P 500 ending 2027 at 8,500 on AI, earnings support
Traders Union
·
20分钟前
Mohamed A. El-Erian: S&P 500 may face longest losing streak since 2020 as 10-year Treasury yield falls
24/7 Wall St.
·
20分钟前
The S&P 500 Just Had Its Biggest Reversal Since March 2020
资料
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
Diamyd Medical AB简介